Medical News Today (MNT)A Natural Supplement May Help People with a New Type of Heart Disease

This article reports on a clinical study investigating tricaprin supplementation in patients with triglyceride deposit cardiomyovasculopathy (TDCV), a rare, recently discovered heart condition. The evidence quality is moderate (non-blinded comparative study with n=22 intervention vs. n=190 controls) but shows promising outcomes for this specific population with limited treatment options.

⚕️Key Clinical Considerations⚕️

• Tricaprin (medium-chain triglyceride found in coconut oil) improved myocardial lipolysis in TDCV patients, addressing the fundamental pathophysiology of impaired triglyceride breakdown.
• Intervention group showed 100% three-year and five-year survival rates compared to control group rates of 78.6% and 68.1%, respectively.
• Among heart failure patients specifically, tricaprin group maintained 100% survival rates while controls showed 76.8% (3-year) and 64.8% (5-year) survival.
• Clinical benefits included heart failure symptom improvement, durable heart failure recovery, and left ventricular improvements including better ejection fraction.
• Study limitations include small sample size, focus on Japanese population, variable timing between diagnosis and treatment, and potential conflicts of interest with the Patient Association providing the supplement.

🎯 Clinical Practice Impact 🎯

• Consider discussing tricaprin supplementation with TDCV patients who have symptoms resistant to standard treatments, particularly those with heart failure.
• Although promising, the limited evidence base warrants caution in broad application.
• Document discussions about this emerging treatment option, noting its investigational nature.
• Monitor patients closely for clinical response if implementing, and consider consulting with specialists experienced in treating rare cardiomyopathies before recommending supplementation.

More on Rare Conditions & Diseases